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Abstract
BACKGROUND: Methylated Septin 9 (mSEPT9) in plasma has recently been suggested as a screening marker for
colorectal cancer (CRC)with variable sensitivity.We aimed to determine the usefulnessof plasmamSEPT9 for screening
CRC and gastric cancer (GC) and its diagnostic role in postoperative CRC patients.METHODS: A total of 350 peripheral
blood samples from 101 CRC patients, 153 GC patients, and 96 healthy persons were collected. In addition, we ob-
tained 35 follow-up blood samples from 27 CRC patients after curative radical surgery. PlasmamSEPT9, serum carcino-
embryonic antigen (CEA), and serum CA19-9 were evaluated with clinicopathologic features. RESULTS: The sensitivity
of plasma mSEPT9 was 36.6% for detecting CRC and 17.7% for detecting GC, and the specificity was 90.6%. During
follow-up periods, mSEPT9 showed negative conversion in eight of nine CRC patients (88.9%) whose plasma mSEPT9
had been positive before radical surgery. The patients with plasma mSEPT9 had a tendency of presence of distant
metastasis and lower disease-free survival in both CRC and GC. In GC patients, plasma mSEPT9 was more frequently
observed in intestinal (23.5%) andmixed type (40.0%) than diffuse type (7.3%;P= .009). Combined analysis ofmSEPT9,
CEA, and CA19-9 increased the sensitivity for diagnosing GC to 32.7% (P = .002). CONCLUSION: Considering the
high incidence of plasma mSEPT9 in intestinal or mixed type GCs similar to CRCs, GC should be examined through
the plasma mSEPT9 screening test. In addition, plasma mSEPT9 is proposed as a follow-up marker in CRC patients,
but further validation is required.
Translational Oncology (2013) 6, 290–296
Introduction
Colorectal cancer (CRC) is one of the most common cancers and is
a leading cause of cancer-related deaths worldwide [1]. In spite of the
advances in the treatment, an advanced stage of CRC at the time of
diagnosis is still associated with a very unfavorable prognosis. Screening
tests decrease CRC-related mortalities by detecting tumors at earlier
stages, thereby improving patient prognosis [2,3]. Details of CRC
screening policies vary in different countries, but it is generally agreed
that there is convincing evidence for the usefulness of testing fecal
occult blood or performing colonoscopy to detect early-stage cancer
and adenomatous polyps in patients aged≥50 years [4–6]. Fecal occult
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blood testing and fecal immunochemical tests have a few advantages
including easier methods and inexpensiveness [7] but with low sen-
sitivity and specificity. Flexible sigmoidoscopy and colonoscopy dem-
onstrate high sensitivity and specificity in preventive and therapeutic
procedures to remove adenomatous polyps or early cancers [6]. How-
ever, it is expensive and presents risks such as perforation or bleeding.
Therefore, the recommendations for incorporating invasive procedures
into screening policies for CRC vary between countries [4,5,8], and
moreover, not all adults receive screening tests despite their recom-
mendation by national guidelines [9,10]. Only 64.2% of adults were
reported to be recommended for screening in the United States [10],
and the rate was lower in Korea at 35.5% [9]. Tomaximize the number
of individuals who participate in screening and reduce colon cancer
deaths and the cost of health care [11,12], studies targeted on more
sensitive and noninvasive methods such as blood testing to screen
CRC are being investigated.
Because CRC is known to develop from the accumulation of
genetic and epigenetic changes in colonic epithelial cells, molecular
markers targeting genetic and epigenetic alterations have been evalu-
ated in tumor tissues and peripheral blood. Differences in the methyla-
tion status of tumor and nontumor DNA were evaluated for various
genes [13], and methylated Septin 9 (mSEPT9) DNA has been pro-
posed as a screening marker for detecting CRC in peripheral blood
and tumor tissue [12,14–16]. SEPT9 is a member of the septin family
involved in cytokinesis and cytoskeletal organization [17]. Alterations
in SEPT9 have been linked to multiple cancers, but the role of SEPT9
in tumorigenesis is still elusive [18]. Instead, several studies have eval-
uated mSEPT9 in human plasma as a screening marker for CRC
[12,14,15]. The sensitivity and specificity of plasma mSEPT9 for
detecting CRC varied from 50% to 90% and from 88% to 91%,
respectively, depending on the detection methods. Plasma mSEPT9
is suggested to be a screening tool in standard-risk individuals un-
able or unwilling to receive standard CRC screening tests. However,
only limited data regarding CRC screening with mSEPT9 have been
analyzed, especially in Asians [19], although some studies have
reported differences in tumor DNA methylation between different
ethnicities [18,20,21].
Considering that mSEPT9 have been reported to present in other
organ cancers [18,22], mSEPT9 in blood sample is suggested not to
be specific for CRC. Among various organs, gastric cancer (GC) and
small intestinal cancer are morphologically similar to CRC. However,
the incidence of small intestinal cancer is very low and we cannot
easily meet it at daily practice. GC is the fourth most common malig-
nancy and more common in developing countries and in Asian countries
[1]. Intestinal type of GC has very similar histopathology to CRC, and
in addition, they share some molecular characteristics including micro-
satellite instability, hypermethylation of tumor suppressor genes, and
some mutations [23,24]. However, mSEPT9 in blood samples of GC
patients has not been reported yet.
The present study aimed to investigate the usefulness of mSEPT9
as a diagnostic marker in Korean gastrointestinal cancer patients and
to validate the results in healthy controls by performing real-time
polymerase chain reaction (PCR) assays with plasma samples from
CRC and GC patients and healthy controls. Subsequently, we analyzed
the correlation between clinicopathologic characteristics and plasma
mSEPT9 in CRC and GC patients, compared the clinical implication
of plasma mSEPT9 with serum carcinoembryonic antigen (CEA) and




To investigate mSEPT9, a total of 254 gastrointestinal cancer
patients and 96 anonymous healthy volunteers were enrolled in this
study. The cancer patients (101 CRC patients and 153 GC patients)
whose diagnosis of CRC or GC was confirmed by endoscopic and
histopathologic examination were enrolled. The plasma specimens
were collected from the CRC and GC patients before surgical treat-
ment, chemotherapy, or radiation therapy at Seoul National University
Bundang Hospital between March 2011 and May 2012. We obtained
the pretreatment cell-free plasma samples by collecting remnants of
routine blood samples. Using this technique, 35 follow-up specimens
were obtained from 27 CRC patients who were treated with curative
radical surgery. Clinical and pathologic data for the CRC and GC
patients were recorded from the electronic medical record system and
histopathologic review. Cancer staging was based on the seventh edition
of the Cancer Staging Manual of the American Joint Committee on
Cancer [25]. Histologic differentiation was graded on the basis of the
World Health Organization (WHO) classification [26]. Follow-up
information, including cancer recurrence and the time interval between
the date of surgical resection and recurrence, was collected. The patients
lost to follow-up and deaths from any cause other than CRC or GC
were regarded as censored data for the survival analysis. The mean
follow-up period was 518 days (range, 492–543 days) in CRC patients
and 413 days (range, 397–460 days) in GC patients. For the disease-
free controls, 96 anonymous healthy volunteers were enrolled from
the same institute from November 2011 to May 2012. The control
subjects did not have any neoplasms in their colorectum or stomach
or other organs. This study was approved by the Institutional Review
Board of Seoul National University Bundang Hospital. Written consent
was obtained from the participants.
Specimen Preparation
Blood samples were collected from remnants of routine blood sam-
ples of two 9-ml K2-EDTA bottles. The specimens were processed and
stored within 24 hours of collection. Whole-blood specimens were
kept at 2 to 8°C before centrifugation and held at 15 to 30°C for
approximately 30 minutes immediately before centrifugation. The
blood samples were centrifuged in the blood tubes at room tempera-
ture for 10 minutes at 1500g and recentrifuged at 1500g for 10 min-
utes in 15-ml tubes. The buffy coat layer was not to be disturbed while
transferring the plasma. The plasma specimens were stored at −70°C
before the analysis. At least 4 ml of plasma was collected for testing.
DNA Extraction
DNA was extracted by using the Abbott m2000sp Sample Prepara-
tion System (Abbott Molecular, Abbott Park, IL). The patient speci-
mens and one each of the positive and negative controls included
in the Abbott RealTime mS9 Colorectal Cancer Assay Kit (Abbott
Molecular) were processed with the Abbott m2000sp. The nucleic
acids were eluted by magnetic particle technology to capture the nucleic
acids, and unbound sample components were removed by washing.
Bisulfite Conversion and Bisulfite Purification
Bisulfite modification was performed by Abbott Bisulfite Modifica-
tion Kit according to the manufacturer’s protocol. Briefly, 210 μl of
bisulfite mix and 38 μl of DNA protect buffer provided in the bisulfite
modification kit were mixed with 100 μl of DNA specimen. The tubes
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were transferred to a thermal cycler and amplified with the following
conditions: 99°C for 5 minutes, 60°C for 25 minutes, 99°C for 5 min-
utes, 60°C for 85 minutes, 99°C for 5 minutes, and 60°C for 2 hours
and 55 minutes, followed by holding at 20°C. Bisulfite purification was
performed using an Abbott m2000sp System with Abbott Low Re-
sidual Volume Tubes.
Real-time PCR for the Detection of mSEPT9
The Abbott RealTime mS9 Colorectal Cancer Assay System,
which consisted of an Abbott RealTime mS9 Colorectal Cancer Am-
plification Reagent Kit and an Abbott RealTime mS9 Colorectal
Cancer Control Kit, was used according to the manufacturer’s pro-
tocol. A PCR master mix was created with the amplification reagent
kit. Activation reagent, oligonucleotide reagent, and AmpliTaq gold
enzyme were mixed, and 50 μl of the master mix and 30 μl of the
purified product were placed on a 96-well optical reaction plate on
the Abbott m2000rt (Abbott Molecular) for real-time amplification.
The test was performed in triplicate using the contiguous three wells
across the row on the same plate. The endogenous human β-actin
gene was used as the internal control for sample extraction, bisulfite
modification, and amplification efficiency. Specimens whose cycle
number of internal control exceeds the established specification range
by mS9 Colorectal Cancer Assay m2000rt software were considered
as inhibited and retested starting with sample preparation if possible.
The positive and negative controls provided by the manufacturer
were processed along with the samples from the DNA extraction
stage. The results were reported when both controls were valid. Sam-
ples were reported as positive when the internal controls were posi-
tive and when at least one of three samples was positive.
Measurement of CEA and CA19-9
Serum CEA and CA19-9 concentrations were analyzed using an
electrochemiluminescence immunoassay kit on the Modular Analytics
E170 module (Roche Diagnostics Corp, Indianapolis, IN) according
to the manufacturer’s instructions.
Statistical Analysis
The sensitivity and specificity of plasma mSEPT9 were compared
using receiver operating curve with the area under the curve. The
correlation between clinicopathologic features and mSEPT9 was
analyzed using the Fisher exact method or χ2 test. The mean values
for age, CEA, CA19-9, and tumor size were compared according to
mSEPT9 status, using the nonparametric Mann-Whitney test. The
Kaplan-Meier method with the log-rank test was performed for the
univariate analysis of the effect of mSEPT9 for predicting disease-free
survival (DFS). Multivariate analysis was performed using the Cox
proportional hazards model to determine hazard ratios. Statistical
analysis was performed with SPSS Standard version 17.0 (SPSS Inc,
Chicago, IL). All of the P values were two-sided, and P < .05 was
considered to be statistically significant.
Results
Diagnostic Performance of mSEPT9 in Gastrointestinal
Cancer Patients
Specimens from 254 gastrointestinal cancer patients and 96 healthy
controls were tested for mSEPT9. mSEPT9 was identified in the pre-
treatment plasma of 64 of 254 gastrointestinal cancer patients (25.2%),
consisting of 37 CRC and 27 GC patients. Therefore, overall sensitiv-
ity was 36.6% [95% confidence interval (CI), 27.8–46.8%] in CRC
and overall sensitivity was 17.7% (95% CI, 12.0–24.6%) in GC
(P = .001). mSEPT9 was detected in 9 (9.4%) of the 96 control speci-
mens collected from the healthy blood donors. The test had an overall
specificity of 90.6% (95% CI, 82.9–95.6%). By comparing the results
from the cancer patients and healthy controls, the positive detection
rate of mSEPT9 was higher in the CRC patients (P < .001) and the
GC patients (P = .05).
Clinicopathologic Characteristics and mSEPT9
The clinical features of the CRC and GC patients according to
mSEPT9 were shown in Table 1. The positive rate of mSEPT9 was
30.8% for stage 0/I, 36.7% for stage II, 25.0% for stage III, and
64.7% for stage IV CRC patients, with borderline statistical signifi-
cance (P = .051). The detection of mSEPT9 was significantly higher
in the CRC patients with synchronous distant metastasis than in those





Age 65.76 ± 11.25 62.34 ± 10.97 63.59 ± 11.14 NS
Gender
Male 17 (32.7%) 35 (67.3%) 52 NS
Female 20 (40.8%) 29 (59.2%) 49
TNM stage
0/I 8 (30.8%) 18 (69.2%) 26
II 11 (36.7%) 19 (63.3%) 30 .051
III 7 (25.0%) 21 (75.0%) 28
IV 11 (64.7%) 6 (35.3%) 17
Distant metastasis
Absent 26 (31.0%) 58 (69.0%) 84 .008
Present 11 (64.7%) 6 (35.3%) 17
CEA concentration 44.69 ± 133.65 3.31 ± 6.23 18.21 ± 82.09 .024
Preoperative CCRT NS
Not done 31 (36.0%) 55 (64.0%) 86
Done 6 (40.0%) 9 (60.0%) 15
Location NS
Right colon 6 (28.6%) 15 (71.4%) 21
Left colon 31 (38.8%) 49 (61.2%) 80
Total 37 (36.6%) 64 (63.4%) 101
153 GCs
Age 65.30 ± 13.03 60.45 ± 13.34 61.31 ± 13.37 NS
Gender NS
Male 19 (20.9%) 72 (79.1%) 91
Female 8 (12.9%) 54 (87.1%) 62
TNM stage .016
I 6 (11.8%) 45 (88.2%) 51
II 7 (15.9%) 37 (84.1%) 44
III 6 (15.0%) 34 (85.0%) 40
IV 8 (44.4%) 10 (55.6%) 18
Distant metastasis .004
Absent 19 (14.1%) 116 (85.9%) 135
Present 8 (44.4%) 10 (55.6%) 18
CEA concentration 5.46 ± 9.89 3.95 ± 10.52 4.21 ± 10.40 NS
CA19-9 concentration 22.22 ± 44.38 28.11 ± 106.47 27.08 ± 98.38 NS
Location of tumor NS
Lower third 19 (20.0%) 76 (80.0%) 95
Middle third 4 (10.8%) 33 (89.2%) 37
Upper third 4 (19.0%) 17 (81.0%) 21
Total 27 (17.6%) 126 (82.4%) 153
CCRT indicates chemoradiation therapy; NS, not significant.
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without metastasis (P = .008). There was a tendency for higher CEA
concentration in the mSEPT9-positive CRC group (44.69 ng/ml vs
3.31 ng/ml, P = .024). Of a total of 101 CRC patients, 15 were
treated with preoperative chemoradiation therapy and then radical sur-
gery and 3 were treated with chemotherapy only. Thus, the pathologic
characteristics were compared according to mSEPT9 in 83 CRC pa-
tients (Table 2). Tumor size was significantly larger in the mSEPT9-
positive CRC patients than in the mSEPT9-negative patients (P =
.004). The CRC patients with lymphatic or perineural invasion did
not show higher mSEPT9 positivity than those without invasion
(P > .05), but the patients with venous invasion showed a higher per-
centage of mSEPT9 detection than the patients without invasion
(63.6% vs 30.6%, P = .044). Among the other findings, mSEPT9
positivity was significantly higher in CRCs with peritumoral abscess
(75.0%, P = .004).
In the GC patients, mSEPT9 was also associated with advanced
stage (P = .016) and distant metastasis (P = .004; Table 1). In contrast
to CRC group, CEA concentrations of the mSEPT9-positive GC
group were similar to the mSEPT9-negative GC group (P > .05).
Of a total of 153 GC patients, radical surgery was not performed in
15 patients. Thus, pathologic characteristics were compared accord-
ing to mSEPT9 in 138 GC patients (Table 2). Interestingly, mSEPT9
detection was more frequently found in intestinal type (23.5%) and
mixed type (40.0%) than diffuse type (7.3%, P = .009). Among the
other findings, mSEPT9 positivity was significantly higher in GCs
with expanding border (P = .001).
The results of the Kaplan-Meier univariate analysis showed that
mSEPT9 positivity was significantly associated with lower DFS in the
CRC patients (P = .034; Figure 1A). The mSEPT9-positive CRC cases
had estimated mean DFS duration of 480 days (95% CI, 426–534)
compared with the 539 days (95% CI, 516–563) in the mSEPT9-
negative CRC cases. However, mSEPT9 showed borderline prognostic
significance in the GC patients (P = .058; Figure 1B). mSEPT9 was
not an independent prognostic marker in the CRC or GC patients by
Cox regression analysis (P > .05; data not shown).
mSEPT9 as a Follow-Up Marker
Thirty-five postoperative samples (one to four samples in each pa-
tient) from 27 CRC patients treated with curative radical surgery were
tested for mSEPT9 (Table 3). Postoperative specimens were obtained
118 days after surgery on average (71–232 days). Among 27 CRC pa-
tients with follow-up plasma samples, 24 (88.9%) patients showed
negative mSEPT9 after curative radical surgery irrespective of the pre-
treatment results. Sixteen patients (61.5%) showed negative results
for mSEPT9 before and after surgery. Of the nine patients who were
found with mSEPT9 before surgery, negative conversion was observed
in eight patients (88.9%).
CRC recurrence was diagnosed in 4 of 27 patients (Table 3), of
whom 1 patient was diagnosed as recurred cancer by plasma mSEPT9.
In this patient, two serial plasma samples showed mSEPT9 positivity
at 128 and 215 days after the first surgery (Figure W1), but clinical
impression was abscess at anastomosis site by computed tomography
(CT) imaging. Serum CEA concentration of the patient was 2.9, 4.2,
and 12.2 ng/ml at −1, 128, and 215 days, respectively, thus with
borderline clinical significance. Recurrence was confirmed by intra-
operative frozen tissue examination and radical resection of the re-
curred cancer was performed. Negative conversion of mSEPT9 was
found after the second surgery for recurrent cancer (at 348 days after
Table 2. Pathologic Characteristics according to mSEPT9 Status in 83 CRC Patients and 138 GC





WD 3 (42.9%) 4 (57.1%) 7
MD 24 (34.8%) 45 (65.2%) 69
PD 1 (33.3%) 2 (66.7%) 3
Mucinous 1 (25.0%) 3 (75.0%) 4
Tumor size 5.75 ± 2.73 3.99 ± 1.92 4.59 ± 2.37 .004
Depth of invasion NS
pTis/T1 4 (28.6%) 10 (71.4%) 14
pT2 4 (25.0%) 12 (75.0%) 16
pT3 14 (35.9%) 25 (64.1%) 39
pT4 7 (50.0%) 7 (50.0%) 14
LN metastasis NS
pN0 19 (35.8%) 34 (64.2%) 53
pN1 6 (28.6%) 15 (71.4%) 21
pN2 4 (44.4%) 5 (55.6%) 9
Lymphatic invasion NS
Absent 20 (31.7%) 43 (68.3%) 63
Present 9 (45.0%) 11 (55.0%) 20
Venous invasion .044
Absent 22 (30.6%) 50 (69.4%) 72
Present 7 (63.6%) 4 (36.4%) 11
Perineural invasion NS
Absent 19 (30.2%) 44 (69.8%) 63
Present 10 (50.0%) 10 (50.0%) 20
Tumor deposits NS
Absent 22 (34.4%) 42 (65.6%) 64
Present 7 (36.8%) 12 (63.2%) 19
Preexisting adenoma NS
Absent 26 (40.0%) 39 (60.0%) 65
Present 3 (16.7%) 15 (83.3%) 18
Other findings .004
Absent 19 (30.2%) 44 (69.8%) 63
Mucin production 1 (12.5%) 7 (87.5%) 8
Peritumoral abscess 9 (75.0%) 3 (25.0%) 12
Total 29 54 83
GC
Lauren classification .009
Intestinal 12 (23.5%) 39 (76.5%) 51
Diffuse 6 (7.3%) 76 (92.7%) 82
Mixed 2 (40.0%) 3 (60.0%) 5
Tumor size 5.54 ± 3.63 4.37 ± 2.88 4.54 ± 3.02 NS
Depth of invasion NS
pT1 6 (12.2%) 43 (87.7%) 49
pT2 1 (4.5%) 21 (95.5%) 22
pT3 7 (20.0%) 28 (80.0%) 35
pT4 6 (18.8%) 26 (81.3%) 32
LN metastasis NS
pN0 9 (14.1%) 55 (85.9%) 64
pN1 3 (14.3%) 18 (85.7%) 21
pN2 1 (4.5%) 21 (95.5%) 22
pN3 7 (22.6%) 24 (77.4%) 31
Lymphatic invasion NS
Absent 10 (14.9%) 57 (85.1%) 67
Present 10 (14.1%) 61 (85.9%) 71
Venous invasion NS
Absent 16 (14.0%) 98 (86.0%) 114
Present 4 (16.7%) 20 (83.3%) 24
Perineural invasion NS
Absent 13 (17.1%) 63 (82.9%) 76
Present 7 (11.3%) 55 (88.7%) 62
Tumor border .001
Expanding 11 (33.3%) 22 (66.7%) 33
Infiltrative 9 (8.6%) 96 (91.4%) 105
Preexisting adenoma NS
Absent 18 (13.8%) 112 (86.2%) 130
Present 2 (25.0%) 6 (75.0%) 8
Total 20 118 138
WD indicates well differentiated; MD, moderately differentiated; PD, poorly differentiated;
NS, not significant.
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the first surgery). mSEPT9 was also found in the primary and recurrent
CRC tissue samples from this patient.
Serum CEA and CA19-9 Concentrations
No serum biomarker currently exists for initial diagnosis of CRC
or GC in daily practice, but in 2010, the AJCC Cancer Staging,
Seventh Edition has accepted serum tumor marker CEA as site-
specific prognostic factor in CRC and CEA and CA19-9 as prog-
nostic factors in GC [25]. Thus, concentrations of CEA in CRC
patients and CEA and CA19-9 in GC patients were additionally eval-
uated. A serum concentration higher than 5 ng/ml was defined as
CEA positive and a serum concentration higher than 27 U/ml as
CA19-9 positive [27]. Positive CEA was found in 21 (20.8%) of
the 101 CRC patients, which were correlated with advanced stage
and shorter DFS (Table W1). CEA positivity was found in 14
(9.2%) and CA19-9 positivity was found in 22 (14.4%) of 153 GC
patients, which were also correlated with advanced stage and shorter
DFS (Table W2).
To increase the sensitivity for the diagnosis of CRC or GC, we
performed combined analysis of mSEPT9 and serum markers.
CEA positivity and/or plasma mSEPT9 was observed in 44 (43.6%)
of 101 CRC patients; thus, the sensitivity of the combined analysis
was similar to the sensitivity of mSEPT9 for CRC diagnosis (P >
.05). In contrast to CRC patients, the sensitivity of combined analysis
of CEA, CA19-9, and/or mSEPT9 (50 of 153 patients, 32.7%) was
significantly higher than any single marker (P = .002 in mSEPT9;
P < .001 in CEA and CA19-9).
Discussion
In the present study, mSEPT9, which is being evaluated as a non-
invasive plasma screening marker of CRC, was tested in Korean
CRC patients. Overall sensitivity was 36.6% (95% CI, 27.8–46.8%)
and overall specificity was 90.6% (95% CI, 82.9–95.6%). In contrast
to our results in Korean CRC patients, sensitivities of plasma mSEPT9
in previous studies ranged from 50.0% to 90.0% and specificities
ranged from 73.0% to 94.0% as determined by various methods
[12,14,28,29]. Thus, the sensitivity of our results was relatively low,
but the specificity was high. The possible causes of low frequency
of mSEPT9 in the Korean CRC patients may be ethnic variations
in the methylation pattern of SEPT9 or the method of detection. Al-
though ethnic variation in the methylation patterns of SEPT9 has not
been studied, differences in methylation status between ethnic groups
have been published for other genes in prostate or breast cancer patients
[18,20]. The screening of CRC with mSEPT9 has been performed
mostly in the United States and Germany and showed sensitivities
ranging from 50% to 90% with various methods [12,28,29], whereas
a small population study in China showed a sensitivity of 75% using
MethylLight assay [19]. Therefore, further investigations are required
in various ethnics with various methods. To demonstrate the levels of
mSEPT9 in CRC tissue in the Korean population, we evaluated
mSEPT9 in 17 CRC tissues and 17 matched normal tissues. mSEPT9
was detected in 16 cancer tissues (94.1%) and 5 normal tissues (29.4%;
P = .001; data not shown). Therefore, the levels of mSEPT9 in Koreans
were higher in cancer tissue than normal tissue, but the detection rate
of plasma mSEPT9 was lower than other ethnics. In addition, 25 GC
tissues and 25 matched normal tissues were evaluated for mSEPT9.
mSEPT9 was detected in 14 cancer tissues (56.0%) and 4 normal tis-
sues (16.0%; P = .002; data not shown), which suggested that mSEPT9
was not specific for CRC diagnosis.
In addition to CRCs, we investigated plasma mSEPT9 in 153 GC
patients because mSEPT9 was reported in other organ cancers [18,22]
and intestinal type GC has similar morphologic and molecular features
Figure 1. Kaplan-Meier univariate survival curves according to mSEPT9 status in (A) CRC patients and (B) GC patients.
Table 3. mSEPT9 Status in Follow-Up Plasma Samples of 27 CRC Patients.
mSEPT9 No. of Patients CRC Recurrence
during Follow-Up
Preoperative Samples Postoperative Samples
Negative Negative 16 3
Negative Positive 2 1
Positive Negative 8 0
Positive Positive 1 0
Total 27 4
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to CRC. mSEPT9 was infrequently detected in the plasma samples of
GCs (17.7%). However, 23.5% of intestinal type and 40.0% of mixed
type GCs showed presence of mSEPT9 in the plasma samples, which
were similar frequency to CRCs. Furthermore, plasma mSEPT9 was
observed in 44.4% (8 of 18) stage IV GCs. Therefore, GCs, especially
intestinal/mixed type or stage IV, should be considered in differential
diagnosis at the screening test by using plasma mSEPT9. This study is
the first to validate a role of plasma mSEPT9 as a noninvasive diagnostic
biomarker in large-scaled GC cases.
To validate the specificity of mSEPT9 in CRC patients and to eval-
uate a possibility of using mSEPT9 as a noninvasive follow-up marker,
we investigated plasma mSEPT9 in follow-up samples from 27 CRC
patients after curative radical surgery. Twenty-four (88.9%) of 27
patients showed negative mSEPT9 after curative radical surgery and
negative conversion was observed in 8 of 9 patients (88.9%), which
was similar to the overall specificity (90.6%) of pretreatment plasma
mSEPT9. It is suggested that plasmamSEPT9 before and after treatment
is specific for CRCs and have potential for a follow-up marker of CRCs.
The usefulness of mSEPT9 as a follow-up marker was additionally
suggested by the patient in whom recurrent CRC was detected by only
plasma mSEPT9 in our cohort. It is the first to demonstrate the negative
conversion of plasma mSEPT9 after curative radical surgery and the
diagnostic role of mSEPT9 for detecting recurrence. Follow-up results
for mSEPT9 in these patients will aid in deciding whether mSEPT9
can be used as a follow-up marker. Further validation is required for
the clinical use of plasma mSEPT9 as a follow-up marker of CRCs.
In daily practice, serum CEA and/or CA19-9 concentration is used
for screening, prognosis prediction, and follow-up examination in CRC
and GC patients. We also evaluated pretreatment serum CEA con-
centrations in CRC patients and CEA and CA19-9 in GC patients.
To increase the sensitivity for the diagnosis of CRC or GC, we per-
formed combined analysis of mSEPT9 and serum markers. The sensi-
tivity of combined analysis was significantly increased in GCs (32.7%;
P = .002) but not in CRCs. In contrast to CRCs, multiple markers
including plasma mSEPT9 and serum CEA and CA19-9 are suggested
to be more useful for diagnosing GC than any single marker.
Despite the several reports evaluating mSEPT9 in CRC patients, its
clinicopathologic implication has not been confirmed yet. Neither did
in GC patients. Thus, we analyzed whether the detection of mSEPT9
showed any relationship with clinicopathologic characteristics and pa-
tient outcome. There was no significant difference in mSEPT9 detec-
tion according to depth, lymph node metastasis, and lymphatic or
perineural invasion in both CRC and GC. However, those patients
with distant metastasis had significantly higher positivity for mSEPT9.
Furthermore, the mSEPT9-positive group exhibited lower DFS than
the mSEPT9-negative group (P = .034 in CRC; P = .058 in GC).
Therefore, mSEPT9 is suggested to be useful for predicting aggressive
tumor behavior in CRC and GC patients. In contrast to the pres-
ent results, septin 9, which is encoded by SEPT9, was identified as
a pseudopod-specific protein in various cancer cell lines that is essential
for pseudopod protrusion and tumor cell migration and invasion [30].
This discrepancy may be because genetic, epigenetic, and expression
status is different according to the various transcripts encoding differ-
ent isoforms of septin 9, and the relationship between mSETP9 and
septin 9 expression is not clearly elucidated due to isoforms of septin 9
[31]. Further study is needed to clarify it.
In conclusion, mSEPT9 was detected at a relatively low frequency
in the Korean CRC patients but highly specific. mSEPT9 detection
was correlated with clinicopathologic characteristics such as distant
metastasis and poor DFS. In addition to CRCs, we revealed that
plasma mSEPT9 was also observed in GC patients, especially in in-
testinal/mixed type or stage IV GC patients. Therefore, we suggest
that GC should be considered through the screening test using plasma
mSEPT9. Follow-up of mSEPT9-positive patients would reveal the
usefulness of mSEPT9 as an early detection marker for recurrence.
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Figure W1. Plasma mSEPT9 and serum CEA concentrations in
the patient with recurred CRC. mSEPT9 was negative and serum
CEA was 2.9 ng/ml at 1 day before the first operation. At 128 days
after the first operation,mSEPT9waspositive, but CEAwas 4.2 ng/ml
and clinical impression was abscess at anastomosis site by CT
imaging. Serum CEA was 12.2 ng/ml at 215 days. Recurrence was
diagnosed by the second operation at 217 days. Negative conver-
sion of mSEPT9 was found after second operation (at 348 days;
N, negative; P, positive; closed circle, mSEPT9; closed square,
CEA concentration).
Table W1. Clinical Features of a Total of 101 CRC Patients according to Serum CEA Status.
CEA P Value
≥5 ng/ml <5 ng/ml Total
Age 63.86 ± 11.45 63.53 ± 11.13 63.59 ± 11.14 NS
Gender .018
Male 6 (11.5%) 46 (88.5%) 52
Female 15 (30.6%) 34 (69.4%) 49
TNM stage <.001
0/I 0 (0%) 26 (100%) 26
II 5 (16.7%) 25 (83.3%) 30
III 6 (21.4%) 22 (78.6%) 28
IV 10 (58.8%) 7 (41.2%) 17
Distant metastasis <.001
Absent 11 (13.1%) 73 (86.9%) 84
Present 10 (58.8%) 7 (41.2%) 17
mSEPT9 .001
Negative 7 (10.9%) 57 (89.1%) 64
Positive 14 (37.8%) 23 (62.2%) 37
Preoperative CCRT NS
Not done 18 (20.9%) 68 (79.1%) 86
Done 3 (20.0%) 12 (80.0%) 15
Location of tumor NS
Right colon 5 (23.8%) 16 (76.2%) 21
Left colon 16 (20.0%) 64 (80.0%) 80
Mean DFS (days) 400.3 ± 39.5 547.6 ± 9.5 517.5 ± 13.0 <.001*
Total 21 (20.8%) 80 (79.2%) 101
CCRT indicates chemoradiation; NS, not significant; DFS, disease-free survival.
*By log-rank test of Kaplan-Meier survival curves.
Table W2. Clinical Features of a Total of 153 GC Patients according to Serum CEA and CA19-9 Status.
Total CEA P Value CA19-9 P Value
≥5 ng/ml <5 ng/ml ≥27 U/ml <27 U/ml
Age 60.31 ± 13.37 66.00 ± 7.59 59.73 ± 13.71 NS 64.95 ± 13.88 59.53 ± 13.18 NS
Gender NS
Male 91 11 (12.1%) 80 (87.9%) NS 13 (14.3%) 78 (85.7%)
Female 62 3 (4.8%) 59 (95.2%) 9 (14.5%) 53 (85.5%)
TNM stage .013 .002
0/I 51 1 (2.0%) 50 (98.0%) 2 (3.9%) 49 (96.1%)
II 44 4 (9.1%) 40 (90.9%) 5 (11.4%) 39 (88.6%)
III 40 4 (10.0%) 36 (90.0%) 8 (20.0%) 32 (80.0%)
IV 18 5 (27.8%) 13 (72.2%) 7 (38.9%) 11 (61.1%)
Distant metastasis .013 .006
Absent 135 9 (6.7%) 126 (93.3%) 15 (11.1%) 120 (88.9%)
Present 18 8 (27.8%) 13 (72.2%) 7 (38.9%) 11 (61.1%)
mSEPT9 NS NS
Negative 126 9 (7.1%) 117 (92.9%) 17 (13.5%) 109 (86.5%)
Positive 27 5 (18.5%) 22 (81.5%) 5 (18.5%) 22 (81.5%)
Location of tumor NS NS
Lower third 95 9 (9.5%) 86 (90.5%) 15 (15.8%) 80 (84.2%)
Middle third 37 4 (10.8%) 33 (89.2%) 5 (13.5%) 32 (86.5%)
Upper third 21 1 (4.8%) 20 (95.2%) 2 (9.5%) 19 (90.5%)
Mean DFS (days) 413.1 ± 8.5 293.2 ± 46.0 424.6 ± 7.4 <.001* 344.4 ± 31.4 423.7 ± 8.1 <.001*
Total 153 14 (9.2%) 139 (90.8%) 22 (14.4%) 131 (85.6%)
NS indicates not significant; DFS, disease-free survival.
*By log-rank test of Kaplan-Meier survival curves.
